Abbott, Oasmia ink deal

- Abbott and Oasmia Pharmaceutical Friday announced a multi-year agreement to market one of the first cancer medications for dogs. The chemotherapeutic agent, called Paccal Vet (or micellar paclitaxel), represents the first generation of treatments of its kind and is currently being studied to treat canine mast cell tumors where curative surgery cannot be performed. Under the terms of the agreement, Abbott will obtain exclusive rights to distribute Paccal Vet for veterinary use in the United States and Canada, and will be responsible for sales and marketing. Oasmia is responsible for clinical development, manufacturing and registration. Financial terms were not disclosed.